Events Calendar
In This Section
Summa receives dental center funding
Group recommends merging Akron, Summit County health agencies
Double hand transplant patient leaves Pennsylvania hospital
Glenmoor chef tightening belt with diet and fitness program
Autism risks detailed in children of older mothers
Study links autism, ages of both parents
Health bulletin board: Program provides free support to families of kids with special needs
GOP cool to Obama call for two-party health talks
Most Read Stories
Man robbed at Tallmadge Avenue eatery
Another winter punch heading toward Ohio
Four teens restrain man, take items from his Akron home
Complaints against officer keep coming
Police: Ohio girl dies after fall into snow bank
Region makes way for latest batch of snow; cancellations rise
Cuyahoga Falls residents come home to find burning couch on balcony
Blogs:
First Bell - On Education:
No City of Akron basketball tonight
Pets:
Pet telethon re-airs
The Heldenfiles:
Chipmunks "Squeakquel" on DVD/BD March 30
Akron Zips:
Late surge gives Zips ugly road win
Tribe Matters:
Blogmail response on Hafner
Cleveland Browns:
Stallworth's contract terminated
Balanced Ledger:
QB in Browns future: another mock draft
Kent State Sports:
KSU Notes – February 9
Cleveland Cavaliers:
NBA Power Rankings from Around the Internet
Buckeye Blogging:
Buckeyes grab 18 players on signing day
Varsity Letters:
Garfield at Buchtel basketball
All Da King's Men:
Palin At The Tea Party Convention
Blog of Mass Destruction:
Republican Pre-Conditions
Akron Law Café:
Law, Love and Chocolate
Car Chase:
Collector Car Hobby Loses One of the Best—Jim Roll
Let's Talk Real Estate:
Decisions Decisions: Credit Cards or Your Mortgage?
Ohio Travels with Betty:
Loucile is looking for a Lake Erie getaway in June for three kids, ages 1, 3, and 5.
Sound Check:
Talk of the Town – Top entertainment picks for the weekend
HRLite House:
OFCCP Report
Akron Gamer:
Makers of 'Castle Crashers' unveil 'BattleBlock Theater'
See Jane Style:
Do IT this week: Layering
By Meera Selva
Associated Press
POSTED: 12:12 p.m. EST, Nov 24, 2009
LONDON: Canadian doctors have been advised not to use a batch of 170,000 swine flu vaccines after six reports of serious allergic reactions among recipients, but there are no similar reports from other countries, pharmaceuticals company GlaxoSmithKline PLC said today.
Authorities routinely monitor vaccines for any signals of problems, such as the allergic reactions that do occur, rarely, every year. Company spokeswoman Gwenan White said that GlaxoSmithKline advised medical staff in Canada ast week to refrain from using one batch of the vaccine while they look into reports that that it might have caused more allergic reactions than normal.
Six people in Canada had suffered an allergic reaction, said Tim Vail, the spokesman for Canada's health minister. The batch contained about 170,000 doses. It was not immediately clear how many had been administered, although Vail said the majority had been.
''We're not seeing any thing wild or spooky or crazy about our vaccine at all,'' Vail said, arguing it may have been a statistical anomaly that the reactions occurred.
GlaxoSmithKline is only investigating the one batch of its swine flu vaccine in Canada. White said no other doses of its swine flu vaccine around the world are affected.
White said U.K.-based GlaxoSmithKline wrote to Canadian health care professionals advising them to stop using the batch on Nov. 18. She says a total of 7.5 million doses of the vaccine have been distributed in Canada.
Dr. Joel Kettner, Manitoba's chief medical officer of health has said they are being cautious and are following the advice. He urged people not to be alarmed, saying that any allergic reactions occur shortly after inoculation, don't last long and have not led to long-term health problems.
The provincial Alberta government was also holding back the vaccine, although it had not seen a jump in reactions.
GlaxoSmithKline is the world's second largest drug maker by revenue. Its shares were up 0.08 percent on the London stock exchange at $21.19.
Associated Press writer Rob Gillies in Toronto contributed to this report.
LONDON: Canadian doctors have been advised not to use a batch of 170,000 swine flu vaccines after six reports of serious allergic reactions among recipients, but there are no similar reports from other countries, pharmaceuticals company GlaxoSmithKline PLC said today.
Authorities routinely monitor vaccines for any signals of problems, such as the allergic reactions that do occur, rarely, every year. Company spokeswoman Gwenan White said that GlaxoSmithKline advised medical staff in Canada ast week to refrain from using one batch of the vaccine while they look into reports that that it might have caused more allergic reactions than normal.
Six people in Canada had suffered an allergic reaction, said Tim Vail, the spokesman for Canada's health minister. The batch contained about 170,000 doses. It was not immediately clear how many had been administered, although Vail said the majority had been.
''We're not seeing any thing wild or spooky or crazy about our vaccine at all,'' Vail said, arguing it may have been a statistical anomaly that the reactions occurred.
GlaxoSmithKline is only investigating the one batch of its swine flu vaccine in Canada. White said no other doses of its swine flu vaccine around the world are affected.
White said U.K.-based GlaxoSmithKline wrote to Canadian health care professionals advising them to stop using the batch on Nov. 18. She says a total of 7.5 million doses of the vaccine have been distributed in Canada.
Dr. Joel Kettner, Manitoba's chief medical officer of health has said they are being cautious and are following the advice. He urged people not to be alarmed, saying that any allergic reactions occur shortly after inoculation, don't last long and have not led to long-term health problems.
The provincial Alberta government was also holding back the vaccine, although it had not seen a jump in reactions.
GlaxoSmithKline is the world's second largest drug maker by revenue. Its shares were up 0.08 percent on the London stock exchange at $21.19.
Associated Press writer Rob Gillies in Toronto contributed to this report.
Comments
Click here to post your comments
